Patents Assigned to NIPPON SHINYAKU CO.,
-
Publication number: 20230002395Abstract: The purpose of the present invention is to provide a compound having M3 PAM activity. Examples of the present invention include azabenzimidazole compounds represented by the following formula [1] and pharmaceutically acceptable salts thereof. The compounds of the present invention have M3 PAM activity. In addition, since the compounds of the present invention have M3 PAM activity, the compounds of the present invention are useful as preventive agents or therapeutic agents for urination disorders and urine collection disorders in underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, and neurogenic bladder.Type: ApplicationFiled: November 12, 2020Publication date: January 5, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Koya OIKAWA, Takuto YAMANAKA, Sho HIRAI, Kazuhiko WAKITA
-
Publication number: 20230000840Abstract: A novel prophylactic agent or therapeutic agent for functional gastrointestinal disorders or xerostomia is provided. The present invention is a therapeutic agent or prophylactic agent for functional gastrointestinal disorders, containing an azabenzimidazole compound represented by the following formula [1] (each symbol in the formula is as described in the specification), or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.Type: ApplicationFiled: November 12, 2020Publication date: January 5, 2023Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Ryohei YOSHINAGA, Maki KURITA, Yasunori ASAO, Tomomi FUKUI
-
Publication number: 20220333112Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.Type: ApplicationFiled: June 23, 2022Publication date: October 20, 2022Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20220281830Abstract: The present invention relates to a novel salt of 2-(4-(5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid (hereinafter referred to as “Compound B”) and a crystal of the salt thereof.Type: ApplicationFiled: August 19, 2020Publication date: September 8, 2022Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Yasushi KOKUBO, Toshitaka YAMAMOTO, Koji NAKAMICHI, Domenico CROCCO
-
Publication number: 20220227567Abstract: A measuring container comprises a storage container and a storage section selector. The storage container includes storage sections each capable of storing a predetermined number of tablets. The storage section selector is attached to the storage container and has a second path that allows the tablets to pass through from one end to an other end. The one end of the second path is connected to an outside, and the other end is selectively connected to one of the storage sections.Type: ApplicationFiled: April 8, 2020Publication date: July 21, 2022Applicant: NIPPON SHINYAKU CO., LTD.Inventor: Masaki HAYAKAWA
-
Patent number: 11382912Abstract: An object of the present invention is to provide a controlled-release preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide as an active ingredient and having an excellent release property. Another object of the present invention is to provide a controlled-release preparation characterized by containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, a water-soluble polymer, a functional starch, and an alkaline substance, and having a pH of 10 or more.Type: GrantFiled: November 15, 2018Date of Patent: July 12, 2022Assignee: NIPPON SHINYAKU CO., LTD.Inventors: Shouji Furuta, Naoto Hattori
-
Patent number: 11377453Abstract: An object of the present invention is to provide a compound with an excellent JAK1 inhibitory activity. The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect, anti-proliferative effect and so on, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis, vasculitis, bronchial asthma, chronic obstructive pulmonary disease, eosinophilic sinusitis and nasal polyp.Type: GrantFiled: September 29, 2020Date of Patent: July 5, 2022Assignee: NIPPON SHINYAKU CO., LTD.Inventor: Fumi Higuchi
-
Publication number: 20220162604Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.Type: ApplicationFiled: June 30, 2021Publication date: May 26, 2022Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20220119818Abstract: The present invention provides a new approach for inhibiting myostatin signaling by targeting ACVR2B at the mRNA level.Type: ApplicationFiled: December 26, 2019Publication date: April 21, 2022Applicant: NIPPON SHINYAKU CO., LTD.Inventor: Shinichiro NAKAGAWA
-
Publication number: 20220049257Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.Type: ApplicationFiled: November 2, 2021Publication date: February 17, 2022Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20220024921Abstract: The purpose of the present invention is to provide a compound having PIM inhibitory activity. Examples of the present invention include 1,3,4-oxadiazolone compounds represented by the following formula [1], and pharmaceutically acceptable salts thereof, and solvates thereof. The compounds of the present invention have PIM inhibitory activity. In addition, since the compounds of the present invention have PIM inhibitory activity, the compounds of the present invention are useful as therapeutic agents for systemic lupus erythematosus, lupus nephritis, etc.Type: ApplicationFiled: November 14, 2019Publication date: January 27, 2022Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Hirotaka KAMITANI, Hisaaki ZAIMOKU, Yoshinari HARUTA, Takeo KIKUCHI
-
Patent number: 11193125Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.Type: GrantFiled: August 15, 2017Date of Patent: December 7, 2021Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Yuuichirou Tone, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20210371412Abstract: The purpose of the present invention is to provide compounds having an M3 PAM action. Examples of the present invention include azabenzimidazole compounds represented, for example, by formula [I], and pharmacologically acceptable salts thereof. These compounds have M3 PAM activity. In addition, because these compounds have M3 PAM activity, these compounds are useful as agents for the prevention or treatment of voiding and/or storage disorders in underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, and neurogenic bladder.Type: ApplicationFiled: May 7, 2019Publication date: December 2, 2021Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Kouya OIKAWA, Sho HIRAI, Kazuhiko WAKITA, Akiko FUJIBAYASHI
-
Publication number: 20210340171Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: July 14, 2021Publication date: November 4, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20210284680Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: May 28, 2021Publication date: September 16, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20210261596Abstract: An object of the present invention is to provide a novel preparation method that can shorten the preparation period of an oligonucleic acid compound. An example of the present invention is a method for subjecting a compound [A] having a hydroxyl group or a primary or secondary amino group and a compound [B] having a substituent containing a phosphorus atom and represented by the following general formula [1]: to a condensation reaction to prepare a compound [C] represented by the following general formula [C]: wherein the condensation reaction is carried out in a mixed solvent containing a polar solvent and a halogen solvent as a reaction solvent.Type: ApplicationFiled: May 10, 2019Publication date: August 26, 2021Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Yutaro KOTOBUKI, Fumiya URABE
-
Publication number: 20210261963Abstract: The present invention relates to a composition containing an antisense oligonucleotide, and the use thereof to treat Duchenne muscular dystrophy. The present invention particularly relates to the above-described composition that is effective for the treatment of Duchenne muscular dystrophy when it is administered at a dose for the treatment, and the use thereof.Type: ApplicationFiled: June 26, 2019Publication date: August 26, 2021Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Tomonori UNO, Takashi NATSUKAWA, Youichi EGAWA, Youhei SATOU
-
Publication number: 20210222169Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.Type: ApplicationFiled: August 21, 2020Publication date: July 22, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Patent number: 11053497Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.Type: GrantFiled: June 11, 2019Date of Patent: July 6, 2021Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20210198306Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: February 12, 2021Publication date: July 1, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA